Gerresheimer’s Turnaround Hinges on Two Deals as Glass Sale Delay Tightens the Squeeze
Published on 07/22/2026 at 18:33 | Redaktion boerse-global.de
Gerresheimer has cleared one major hurdle but now faces a narrower path to financial stability. The German pharma and cosmetics packaging specialist published its audited 2025 accounts in late June, officially closing the chapter on accounting irregularities linked to bill-and-hand revenue recognition. Yet the relief proved short-lived: the stock slipped 2.27% on Wednesday to €26.66, extending its weekly decline to 8.45% and underscoring just how fragile the recent recovery remains.
The audited figures themselves told a solid operational story. Revenue climbed 16.6% to €2.321 billion, while adjusted EBITDA reached €384.0 million. But the forward guidance was more cautious. Management now expects 2026 revenue to land in the lower half of its €2.3-to-€2.4 billion range, with an adjusted EBITDA margin of 17% to 18%. Free cash flow is forecast to remain negative, between €50 million and €100 million — a persistent drain that makes the company’s upcoming capital measures all the more critical.
Two Pillars, One Missing Leg
Gerresheimer has laid out two key financial relief measures for the current fiscal year. The first is the sale of its US subsidiary Centor Inc., for which Morgan Stanley was mandated in February. The second is a comprehensive refinancing of the company’s debt side, also slated for 2026. Both remain works in progress — announced but not yet completed.
What has changed is the removal of a third potential lever. Gerresheimer has postponed the planned sale of its Moulded Glass business. While the separation process continues, the formal sales process will not begin until later. That leaves the company with just two financial relief options for 2026, and if either slips, the strain on the balance sheet intensifies.
Should investors sell immediately? Or is it worth buying Gerresheimer?
The stock’s distance from its 52-week high of €49.40, set in July 2025, now stands at 46%. At the same time, the share price remains more than 83% above the February trough of €14.90, suggesting a partial recovery that has yet to gain conviction.
Insider Buying Offers a Counter-Narrative
While the market has remained wary, a handful of investors have been voting with their wallets. In late April, entities linked to supervisory board member Klaus Röhrig — AOC Gecko S.à r.l. and Active Ownership Fund — acquired shares worth approximately €12.7 million at €24.04 apiece. Mid-June brought another insider purchase from board member Rudolf Schneider.
Meanwhile, media reports indicate that Goldman Sachs has been building its stake in Gerresheimer over the course of the year, a move widely interpreted as a vote of confidence in the company’s newly restored financial transparency. The US investment bank’s increased exposure adds an institutional anchor to a shareholder base that has been navigating considerable uncertainty.
Analyst Caution Tempers Optimism
The insider buying has not yet translated into broad analyst enthusiasm. LBBW recently raised its price target while maintaining a Hold rating, and Bernstein upgraded the stock from Underperform to Market Perform, citing the lower valuation as a driver. But the Hold rating alongside a target increase suggests limited near-term upside potential — a view reinforced by the fact that free cash flow is expected to remain negative in 2026 even after the Centor sale and refinancing.
The stock’s technical picture reflects this ambivalence. The 50-day moving average sits at €26.89, a mere 0.87% above the current price. The relative strength index is neutral at 42.4, while annualized volatility stands at 40.45%. On a 12-month basis, the stock has lost 43.64% — a damage that announced but unconsummated transactions alone cannot repair.
Operational Steps Beyond the Balance Sheet
Away from the financial restructuring, Gerresheimer has been making operational headway. In mid-July, the company unveiled its “Digital Mold” technology, designed to cut development times for injection-molding tools in medical technology. Earlier in the month, it published its first voluntary sustainability report aligned with the Corporate Sustainability Reporting Directive, and commissioned a new photovoltaic system at its Pfreimd site to boost energy self-sufficiency.
Gerresheimer at a turning point? This analysis reveals what investors need to know now.
These initiatives support the broader “gto” transformation program, which aims to stabilize margins despite a challenging market environment. Management also expects a stronger second half of 2026 on the revenue side, which could help ease the cash flow pressure.
The Calendar Ahead
The next major test for the stock will come with the first-quarter trading statement, expected around the third quarter of 2026, followed by the half-year financial report later in the year. Investors will scrutinize both for concrete progress on the Centor sale and the refinancing — and for any signs that the promised free cash flow improvement in the second half of 2026 is materializing.
For now, the narrative remains one of cautious optimism tempered by execution risk. The audited accounts and insider purchases suggest growing confidence in the turnaround, while the lowered guidance, negative cash flow outlook, and delayed glass sale highlight how much work remains. The Centor divestment and debt refinancing are the two pillars on which the entire recovery thesis rests — and until both are completed, the stock’s trajectory will remain hostage to timing.
Ad
Gerresheimer Stock: New Analysis - 22 July
Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
